Le Programme 2025
Jeudi - 9 Octobre
Vendredi - 10 Octobre
08:30
WELCOME COFFEE
Jeudi
08:35
Introduction
Elena CASTRO, Karim BENSALAH
Jeudi
08:45
Joint Session: Lymph Node Management Impact in GU Cancers: Myth or Reality?
Chairs: Vérane ACHARD, Juan GOMEZ-RIVAS, Felipe COUNAGO LORENZO
- Bladder cancer Gautier MARCQ
- Prostate cancer Piet OST
- Renal cancer Carme MIR
- Discussion
Jeudi
09:35
Bone and Brain: How to Manage Difficult Situations in GU Cancers? Session with the support of IPSEN
Chair: TBC
- Practical Management of Bone Events
- Management of bone loss: Rheumatologist perspective TBC
- Systemic treatment and bone metastasis: Medical oncologist perspective Philippe BARTHELEMY
- Place of radiotherapy Felipe COUNAGO LORENZO
- Practical Management of Brain Metastases: Systemic and Local Treatments
- Systemic treatment Philippe BARTHELEMY
- Local treatment Felipe COUNAGO LORENZO
10:35 - 11:00
COFFEE BREAK AND EXHIBITION VISIT
Jeudi
11:00
Bladder Cancer
Chairs: Joaquim BELLMUT, Benjamin PRADERE, Enrique GRANDE
- New strategies in high risk NMIBC (CREST, ALBAN…) Morgan ROUPRET
- Radiotherapy in NMIBC: Back to the future? Vérane ACHARD
- Surgical optimization of radical cystectomy Felix GUERRERO-RAMOS
- Discussion
Jeudi
12:00
Radioligands in GU Cancers, Today & Tomorrow - Session with the support of NOVARTIS/ADACAP
Chair: Jérémie CALAIS
- What is the current Use of 177Lu-PSMA therapy in prostate cancer in routine? (Epiduritis, brain let, superbone scan…) Léa TURPIN, Jérémie CALAIS
- What about the future of RLT in prostate cancer? (Earlier stage of the disease, sequencing & combo) Nadine HOUEDE
How can we transpose in other GU cancers? (Target, imaging modalities and theragnostic approach in ongoing clinical trials) Jochen WALZ
Discussion
13:00 - 14:00
LUNCH AND EXHIBITION VISIT
Jeudi
14:00
READ
- TBC
Jeudi
14:15
Tailoring the Approach: A Multidisciplinary Debate on Very High-Risk Prostate Cancer - Session with the support of ACCORD HEALTHCARE
Chair: Alberto BOSSI
- A high-risk clinical case: Debate on surgery vs radiotherapy Alberto BOSSI
- Surgery Michael BABOUDJIAN
- Radiotherapy Vérane ACHARD
- Discussion on the choice of ADT and experience sharing Juan GOMEZ-RIVAS
Jeudi
15:15
Testis and Penile Cancers
Chair: TBC
- Sexuality after GU cancer Antoine FAIX
- Salvage treatment in mGCT Aude FLECHON
- Discussion
15:45 - 16:15
COFEE BREAK AND EXHIBITION VISIT
Jeudi
16:15
Shifting Paradigms in Bladder & Prostate Cancers - Session with the support of PFIZER
Chairs: Elena CASTRO, Morgan ROUPRET
- State of the art: iPARP Elena CASTRO
- CREST: A game-changer in high-risk NMIBC? Evanguelos XYLINAS
- Peri operative treatment for MIBC and UTUC: Chemo, IO or both? Enrique GRANDE
- Discussion
Jeudi
17:15
GU Cancers
Chairs: Laurence ALBIGES, Delphine BORCHIELLINI, Thomas ZILLI
- IO-based combination in first-line mCCRC: What’s next? Philippe BARTHELEMY
- How to mitigate grade 2 adverse effects in the era of SBRT? Felipe COUNAGO LORENZO
- Precision medecine in metastatic PCa: What’s next? TBC
- Discussion
Jeudi
18:00
Special Guest
- TBC
18:30
END OF THE DAY ONE
09:00
START
Vendredi
09:00
Local Treatment Optimization
Chairs: Juan GOMEZ-RIVAS, Thomas ZILLI, TBC
- The future is FOCAL: The urologist point of view Juan GOMEZ-RIVAS
- The future is FOCAL: The radiation oncologist point of view Thomas ZILLI
- Augmented reality in surgery in 2025 Riccardo CAMPI
- Overtreatment in renal Cancer: The example of adjuvant therapy Karim BENSALAH
- Discussion
Vendredi
10:00
Reading of AFU: IA in Surgery and Diagnosis
Chair: Alexandre DE LA TAILLE
- Zine-Eddine KHENE, Sébastien CROUZET
10:30 - 11:00
COFFEE BREAK AND EXHIBITION VISIT
Vendredi
11:00
Urological Cancers: New Horizons in Targeted Treatments, from Early Management to Optimizing First-Line Metastatic Treatments - Session with the support of ASTELLAS
Chairs: Yohann LORIOT, Tom POWLES
- Clinical case: High-risk localized prostate cancer TBC
- Discussion
- New therapeutic options for MIBC: What mmpact on first-line metastatic treatment choices? TBC
- Discussion
- How to optimize La/mUC management? TBC
- Discussion
Vendredi
12:00
Prostate Cancer
Chair: Alexandre DE LA TAILLE
- De-escalation in mHSPC: Is PSA enough? Elena CASTRO
- State of the art: Transperineal versus transrectal TBC
- State of the art: the end of systematic biopsies Michaël BADOUDJIAN
- Discussion
13:00 - 14:00
LUNCH AND EXHIBITION VISIT
Vendredi
14:00
From unfavorable Intermediate Risk to mHSPC: How to Tailor Prostate Cancer Treatment? Session with the support of BAYER
Chair: Alexandre DE LA TAILLE
- Clinical case: Unfavorable intermediate risk prostate cancer Jonathan KHALIFA
- High risk biochemical recurrence: Definition and therapeutic strategies Piet OST
- Progression to mHSPC: Tailoring ARPI-based treatment regimen according to patient and disease profiles Fred SAAD
Vendredi
15:00
Where do we Stand on Personalized Medicine in Urologic Cancers in 2025? Session with the support of JANSSEN
Chair: TBC
- PART 1: New Statégies in mHSPC According to Biomarkers
- Personalized systemic approach according to PSA response (Desintensification / Intensification) Fernando LOPEZ CAMPOS
- Personnalized systemic approach according to mutational status TBC
- Personnalized approach in oligometastatic diseas (Synergie RT & systemic treatment) Stéphane SUPIOT
- PART 2: What Would Be the Next Steps in mUC?
- Beyond immunoscore: What are the future biomarkers in the spotlight? Alexandre HARLE
- Discussion
Vendredi
16:00
Must Read Article
Chairs: Elena CASTRO, Karim BENSALAH
- Arthur PEYROTTES
Vendredi
16:15
Conclusion
Elena CASTRO, Karim BENSALAH
